Race Influences the Safety and Efficacy of Spironolactone in Severe Heart Failure

@article{Vardeny2013RaceIT,
  title={Race Influences the Safety and Efficacy of Spironolactone in Severe Heart Failure},
  author={Orly Vardeny and Larisa H. Cavallari and Brian Lee Claggett and Akshay S. Desai and Inder S. Anand and Patrick Rossignol and Faiez Zannad and Bertram Pitt and Scott D. Solomon},
  journal={Circulation: Heart Failure},
  year={2013},
  volume={6},
  pages={970–976}
}
Background—The incidence of hyperkalemia caused by mineralocorticoid receptor antagonists may vary by race, but whether race influences efficacy of mineralocorticoid receptor antagonists in heart failure (HF) is unknown. Methods and Results—We assessed hyperkalemia and outcomes in African Americans (AAs; n=120) and non-AAs (n=1543; white 93%) with New York Heart Association (NYHA) class III or IV HF and left ventricular dysfunction who were randomized to spironolactone, titrated to 25 or 50 mg… 

Figures from this paper

Safety and Efficacy of Spironolactone in Dialysis-Dependent Patients: Meta-Analysis of Randomized Controlled Trials
TLDR
The therapeutic effects of spironolactone on cardiovascular indexes, including ACM, CCV, and LVMI are highlighted, and the unignorable increase of GYN incidence and serum potassium level indicate that close monitor in dialysis-dependent patients, especially Asian patients, is essential.
Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review.
Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?
TLDR
Until further trials targeting specific subpopulations have been conducted, MRAs should be provided to the great majority of HFrEF patients in the absence of contraindication.
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
TLDR
Patiromer was titrated to achieve and maintain serum potassium level 5.0 mEq/L or lower, which was the most common treatment-related adverse event, mild to moderate constipation, and hypokalemia (<3.3%) over the 52 weeks.
Spironolactone Reduces Aortic Stiffness in Patients With Resistant Hypertension Independent of Blood Pressure Change.
TLDR
It is suggested that spironolactone improves aortic properties in resistant hypertension independently of BP, which may support the hypothesis of an effect of aldosterone on the arterial wall.
Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials
TLDR
A systematic review of the studies included suggested a consistent improvement in surrogate markers of cardiovascular disease, and the use of mineralocorticoid receptor antagonists was associated with an increased serum potassium.
Reducing cardiovascular risk in chronic kidney disease : a focus on mineralocorticoid receptor antagonist and arterial stiffness in primary care
  • K. Ng
  • Medicine, Biology
  • 2016
TLDR
The use of allopurinol, a xanthine oxidase inhibitor, was found to be associated with lower arterial stiffness amongst a cohort of high-risk, CKD patients, which is a significant prerequisite for their participation in CKD research in primary care.
Pharmacological treatment of aldosterone excess.
Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial
TLDR
Black patients with HFpEF have a higher HF hospitalization risk than nonblack patients, but spironolactone is similarly effective and safe in both groups, according to self-described black and nonblack race.
...
...

References

SHOWING 1-10 OF 50 REFERENCES
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice.
TLDR
Although serious hyperkalaemia events were reported in the major MRA clinical trials, these risks can be mitigated through appropriate patient selection, dose selection, patient education, monitoring, and follow-up.
Eplerenone in patients with systolic heart failure and mild symptoms.
TLDR
Eplerenone, as compared with placebo, reduced both the risk of death and therisk of hospitalization among patients with systolic heart failure and mild symptoms.
Pharmacotherapy in congestive heart failure: aldosterone receptor antagonism: interface with hyperkalemia in heart failure.
TLDR
The risk of some change in serum K+ with ARA should not be a deterrent to use of drugs in this class but, rather should prompt careful surveillance for the onset of this potentially life-threatening electrolyte disturbance.
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
TLDR
The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therapy for heart failure including neurohormonal blockers is efficacious and increases survival among black patients with advanced heart failure.
Association of Beta Blocker Exposure with Outcomes in Heart Failure Differs Between African American and White Patients Lanfear
TLDR
BB appears to be 40-50% less effective in preventing death or hospitalization among African American patients with HF as compared with white individuals, and further study is needed to better understand BB effectiveness.
...
...